The Global Health Body Sounds Alert Over Critical Scarcity of Obesity Medications
Under a tenth of individuals eligible to benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it issues its inaugural guidance on the medications.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable availability to this class of drugs.
Per projections, over two billion will be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a chronic disease that can be managed with holistic and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to widespread access to the jabs that can aid individuals in losing significant weight, notes the agency.
Skinny Jab Scarcity
Even in the current most favorable case, the production of GLP-1 therapies would only suffice for around 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation calls on governments and firms to widen access, through approaches such as patent sharing.
A patent on a key compound – the main component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
How Obesity Jabs Operate
These medications mimick a biological compound to reduce digestion speed, curb appetite and increase satiety so individuals eat less.
People commonly see weight reduction after several weeks of starting on the regular doses.
Evidence suggests patients may see weight return a year later of discontinuing the drug, when their normal food cravings return.
To be above a healthy weight elevates your risk for contracting diseases, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts people in every country and was associated with 3.7 million fatalities worldwide in 2024, according to the WHO.
